Advertisement

Topics

Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs

06:55 EDT 16 Apr 2019 | Xconomy

Drug discovery startup Insitro burst onto the scene last year with ambitions of using machine learning techniques to find new therapies. Now the company has its first pharmaceutical partner. Gilead Sciences will work with Insitro to find medicines to treat a liver disease, nonalcoholic steatohepatitis (NASH), that is fast becoming a global epidemic fueled by […]

Original Article: Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs

NEXT ARTICLE

More From BioPortfolio on "Insitro Lands Three-Year Deal With Gilead to Find New NASH Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...